John Leonard, Intellia CEO
November 2, 2023 11:18 AM EDT
R&D
Cell/Gene Tx

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II

Lei Lei Wu

News Reporter

In­tel­lia on Thurs­day pre­sent­ed new re­sults for its gene edit­ing treat­ment in 65 pa­tients with AT­TR amy­loi­do­sis — a con­di­tion in which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times